Chinese medical‑device companies listed on the STAR Market reported a strong first half of 2026, with total revenue climbing 27% year‑on‑year. The boost comes from two forces: a wave of home‑grown innovations that are finally replacing imported high‑end equipment, and an aggressive push into overseas markets that now account for about a third of many firms’ sales. Companies such as United Imaging Healthcare have taken more than 90% of the core components for their premium imaging and radiotherapy systems in‑house, while Beixin Life Sciences launched China’s first domestically developed 60 MHz IVUS system, earning EU MDR approval and quickly gaining market share abroad. Other breakthroughs include MicroPort HeartCare’s world‑first branched aortic stent graft and Sinomeds’ FDA‑cleared drug‑eluting intracranial stent. Revenue from abroad is rising fast – United Imaging’s overseas sales jumped 55% to ¥1.77 billion, Micro‑Tech earned 63% of its ¥1.73 billion from overseas, and Haier Biomedical saw double‑digit growth across Asia, the Americas and Africa. At home, centralized procurement is reshaping pricing, but firms are countering by investing in high‑margin innovative products while keeping mature lines to steady cash flow. The dual‑track strategy is helping them dodge price‑cut pressures and improve profitability, signalling a new era of high‑quality growth for China’s med‑tech sector.
Read more